Helping patients make the best decision regarding duration of temozolomide chemotherapy treatment

CONTINUUM Lifelong Learning in Neurology

Volumn 18, Issue 2, 2012, Pages 421-425

  Groves, Morris D ^a   Plummer, Ava B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE;

ADJUVANT CHEMOTHERAPY; ADULT; BLEEDING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CASE REPORT; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GLIOBLASTOMA; HUMAN; INFORMED CONSENT; OPPORTUNISTIC INFECTION; PARIETAL CORTEX; PATIENT DECISION MAKING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TUMOR GROWTH;

EID: 84859628236     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000413668.65668.4a     Document Type: Review

References (24)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-996. (Pubitemid 40349501)
2. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10(5):459-466.
3. Pollack A. Considering longer chemotherapy. New York Times. July 20, 2009:D1. www.nytimes.com/2009/07/21/health/21canc.html?pagewanted=1&sq= Pollack%20A%20and%20chemotherapy&st=nyt&scp=3. Accessed September 14, 2011.
4. Colman H, Hess KR, Turner MC, et al. Impact of duration of temozolomide therapy on progression-free survival in recurrent malignant glioma. Neuro Oncol 2002;4(4):368.
5. Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 2011;29(16):2144-2149.
6. Seidman AD. How long is long enough? J Clin Oncol 2011;29(16):2129-2130.
7. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999;17(9):2762-2771. (Pubitemid 29415233)
8. Armstrong TS, Cao Y, Scheurer ME, et al. Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. Neuro Oncol 2009;11(6):825-832.
9. Gerber DE, Grossman SA, Zeltzman M, et al. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol 2007;9(1):47-52. (Pubitemid 46543488)
10. Jalali R, Singh P, Menon H, et al. Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with temozolomide. J Neurooncol 2007;85(1):105-107. (Pubitemid 47422663)
11. Noronha V, Berliner N, Ballen KK, et al. Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature. Neuro Oncol 2006;8(3):280-283. (Pubitemid 46542652)
12. Singhal N, Selva-Nayagam S, Brown MP. Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment - case study and review of literature. J Neurooncol 2007;85(2):229-230. (Pubitemid 47629406)
13. Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications [published erratum appears in J Clin Oncol 2004;15(22):2038]. J Clin Oncol 2004;22(4):610-616. (Pubitemid 41095063)
14. Grisdale K, Ritterhouse M, Hunter K, et al. Tonsillar pseudotumor: complications of chronically-administered temozolomide. J Neurooncol 2010;100(3):475-479.
15. Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-2157.
16. Georgescu G, Isola IM, Youssef S, et al. Disseminated salmonellosis in a patient treated with temozolomide. J Infect 2008;57(5):414-415.
17. Binello E, Germano IM. Tonsillary carcinoma after temozolomide treatment for glioblastoma multiforme: treatment-related or dual-pathology? J Neurooncol 2009;94(1):145-148.
18. Lantos J. Informed consent. The whole truth for patients? Cancer 1993;72(9 suppl):2811-2815.
19. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17(8):2572-2578. (Pubitemid 29368260)
20. Wong ET, Gautam S, Malchow C, et al. Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Canc Netw 2011;9(4):403-407.
21. Schaeffer MH, Krantz DS, Wichman A, et al. The impact of disease severity on the informed consent process in clinical research. Am J Med 1996;100(3):261-268. (Pubitemid 26111622)
22. Flory J, Emanuel E. Interventions to improve research participants' understanding in informed consent for research: a systematic review. JAMA 2004;292(13):1593-1601. (Pubitemid 39314966)
23. Schaub v. Sanchez, 229 S.W.3d 322, 50 Tex. Sup. Ct. J. 919 (Tex. 2007).
24. th Cir. 2003).